In response to the COVID-19 pandemic, and in view of the critical need to develop and help speed to market medical products and services to combat COVID-19, the United States Patent and Trademark Office (USPTO) initiated the COVID-19 Prioritized Trademark Examination Program in June of 2020.
To further support efforts to combat COVID-19, the USPTO is now initiating a Pilot Prioritized Review Program for Appeals Related to COVID-19, in which the Trademark Trial and Appeal Board (TTAB) will expedite the review and issuance of ex parte appeal decisions for applications examined under the COVID-19 Prioritized Trademark Examination Program.
To further support these efforts, the USPTO will initiate a Conference Pilot Program for Oppositions Against Applications Related to COVID-19. With this program, a TTAB attorney or judge may participate in the parties’ mandatory settlement and discovery planning conference, as is always available upon request of a party, if the involved application was examined under the COVID-19 Prioritized Trademark Examination Program. Such conferences can be useful to the parties to provide clarity and procedural information.